Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graham, M. C.
Right arrow Articles by Larson, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graham, M. C.
Right arrow Articles by Larson, S. M.
Clinical Cancer Research Vol. 5, 1307-1318, June 1999
© 1999 American Association for Cancer Research

Clinical Trials

Rhenium-186-labeled Hydroxyethylidene Diphosphonate Dosimetry and Dosing Guidelines for the Palliation of Skeletal Metastases from Androgen-independent Prostate Cancer1

Martin C. Graham2, Howard I. Scher, Gen-Bao Liu3, Samuel D-J. Yeh, Tracy Curley, Farhad Daghighian, Stanley J. Goldsmith and Steven M. Larson

Departments of Medical Physics [M. C. G., G-B. L.], Medicine [H. I. S., T. C.], and Radiology [S.D-J. Y., F. D., S. M. L.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021, and Departments of Medicine [H. I. S., T. C.] and Radiology [S. J. G.], Cornell University Medical Center, New York, New York 10021

Rhenium-186 (tin)-labeled hydroxyethylidene diphosphonate (186Re-labeled HEDP) was evaluated in 27 men with progressive androgen-independent prostate cancer and bone metastases. Administered activities ranged from 1251 to 4336 MBq (33.8–117.2 mCi). The primary objectives were to assess tumor targeting, normal organ dosimetry, and safety. Antitumor effects were assessed by posttherapy changes in prostate-specific antigen and, when present, palliation of pain. Whole-body kinetics, blood and kidney clearance, skeletal dose, marrow dose, and urinary excretion of the isotope were assessed. Targeting of skeletal disease was observed over the period of quantification (4–168 h). Radiation doses to whole body, bladder, and kidney were well tolerated. The dose-limiting toxicity was myelosuppression (grade III) at 4107 MBq (111mCi) and grade II at 296 MBq (80mCi). Probe clearance (whole body) and urinary excretion measurements were highly correlated.

Of the six patients treated at the highest dosage schedules (three at 1510 MBq/m2 and three at 1665 MBq/m2), three showed a posttherapy decline in prostate-specific antigen of 50% or more. The declines were not sustained. The determination of total activity retained at 24 h, as well as an estimate of marrow dose, correlated with the amount of myelosuppression observed. These results suggest that a single 24-h measurement of retained activity would allow individualized dosing and an improved therapeutic index relative to fixed dosing schema. Repetitive dosing is required to increase palliation.




This article has been cited by other articles:


Home page
 JNMHome page
N. Pandit-Taskar, M. Batraki, and C. R. Divgi
Radiopharmaceutical Therapy for Palliation of Bone Pain from Osseous Metastases
J. Nucl. Med., August 1, 2004; 45(8): 1358 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
K. Liepe, R. Hliscs, J. Kropp, R. Runge, F. F. Knapp Jr., and W.-G. Franke
Dosimetry of 188Re-Hydroxyethylidene Diphosphonate in Human Prostate Cancer Skeletal Metastases
J. Nucl. Med., June 1, 2003; 44(6): 953 - 960.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Brenner, W. U. Kampen, C. Brummer, C. von Forstner, M. Zuhayra, N. Czech, C. Muhle, and E. Henze
Bone Uptake Studies in Rabbits Before and After High-Dose Treatment with 153Sm-EDTMP or 186Re-HEDP
J. Nucl. Med., February 1, 2003; 44(2): 247 - 251.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. G. Rajendran, J. F. Eary, W. Bensinger, L. D. Durack, C. Vernon, and A. Fritzberg
High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation
J. Nucl. Med., October 1, 2002; 43(10): 1383 - 1390.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Smaletz, H. I. Scher, E. J. Small, D. A. Verbel, A. McMillan, K. Regan, W. K. Kelly, and M. W. Kattan
Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration
J. Clin. Oncol., October 1, 2002; 20(19): 3972 - 3982.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Brenner, W. U. Kampen, C. v. Forstner, C. Brummer, M. Zuhayra, C. Muhle, N. Czech, and E. Henze
High-Dose Treatment with 186Re-HEDP or 153Sm-EDTMP Combined with Amifostine in a Rabbit Model
J. Nucl. Med., October 1, 2001; 42(10): 1545 - 1550.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Brenner, W. U. Kampen, A. M. Kampen, and E. Henze
Skeletal Uptake and Soft-Tissue Retention of 186Re-HEDP and 153Sm-EDTMP in Patients with Metastatic Bone Disease
J. Nucl. Med., February 1, 2001; 42(2): 230 - 236.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.